Device Trial Radar · NCT06368479
Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings
Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,400
Actual
Start
Mar 19, 2024
Primary completion
Jul 19, 2024
Study completion Jul 19, 2024
Sponsor
- Lead sponsor
- bioLytical LaboratoriesNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Screening
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of testing the samples on iStatis HBsAg Test at the point of care.
Conditions
- Hepatitis B
- Hepatitis B Infection
Interventions
iStatis HBsAg TestDevice
Capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples to be tested on the iStatis HBsAg Test at the point of care setting.
Primary outcomes
What the sponsor says the trial is designed to measure.
- iStatis PerformanceTime frame: 3 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Epicentre Health Research
Hillcrest, KwaZulu-Natal, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.